MedImmune Receives Antitrust Clearance for Aviron Acquisition

07-Jan-2002

Gaithersburg, MD, January 4, 2002 -- MedImmune, Inc. announced today that the waiting period regarding its acquisition of Aviron under the Hart-Scott-Rodino Antitrust Improvements Act has expired. As previously announced, MedImmune and Aviron have entered into a definitive merger agreement under which MedImmune will acquire Aviron through an Exchange offer and merger transaction in which Aviron stockholders will receive 1.075 MedImmune shares for each Aviron share. The exchange offer commenced on December 10, 2001 and is scheduled to expire at 12:00 midnight, New York City time, on January 9, 2002, unless extended.

Aviron is a biopharmaceutical company headquartered in Mountain View, California, focused on prevention of disease through innovative vaccine technologies. The company's product portfolio includes: FluMist(TM), a live virus vaccine delivered as a nasal mist for the prevention of influenza; a live parainfluenza virus type 3 vaccine; a vaccine to prevent Epstein-Barr virus, and a cytomegalovirus vaccine.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances